Cogent Biosciences Financial Ratios
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
31.00+0.92 (+3.06%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cogent Biosciences ratio analysis
Return on equity reached -51.7%, meaning Cogent Biosciences generated -0.52 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.35 versus 0.00 the year before, and the current ratio was 14.23. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Cogent Biosciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Price / sales | — | — | — | — | — | 15.81 | 0.97 | 45.12 | — |
| Price / book | 7.04 | 3.19 | 1.82 | 2.66 | 1.55 | 0.53 | 0.68 | 7.29 | — |
| Operating margin | — | — | — | — | — | -1,044.3% | -143.0% | -369.9% | -312.8% |
| Net margin | — | — | — | — | — | -950.4% | -141.5% | -354.8% | -304.9% |
| Free cash flow margin | — | — | — | — | — | -455.5% | -184.7% | -339.4% | -319.9% |
| Return on equity (ROE) | -51.7% | -99.8% | -74.6% | -54.8% | -33.7% | -31.9% | -100.2% | -57.3% | — |
| Return on assets (ROA) | -35.1% | -78.0% | -61.4% | -46.6% | -31.1% | -29.8% | -64.4% | -40.2% | -51.9% |
| Debt / equity | 0.35 | 0.00 | — | — | — | — | — | — | — |
| Current ratio | 14.23 | 5.32 | 7.09 | 9.87 | 13.04 | 18.70 | 3.06 | 3.25 | 3.79 |
| Revenue growth | — | — | — | — | — | -65.0% | 131.1% | 16.4% | — |